In patients with Myelodysplastic Syndrome (MDS), is leukocytosis or leukopenia more common?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 11, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Leukopenia is More Common in MDS

In patients with Myelodysplastic Syndrome (MDS), leukopenia (low white blood cell count) is significantly more common than leukocytosis. MDS is fundamentally characterized by cytopenias—reductions in blood cell counts—not elevations 1, 2.

The Cytopenic Nature of MDS

MDS is defined by ineffective hematopoiesis leading to blood cytopenias, which include anemia, neutropenia (a form of leukopenia), and/or thrombocytopenia 1, 3. The diagnostic criteria for MDS specifically require the presence of blood cytopenias that persist over several months 1, 3.

Typical Presentation Pattern

  • Anemia is the dominant cytopenia: More than 90% of MDS patients present with anemia at diagnosis 1
  • Neutropenia (leukopenia) is common: Patients typically present with reduced neutrophil counts as part of the cytopenic picture 2, 4
  • The bone marrow paradox: Despite peripheral cytopenias, the bone marrow is usually hypercellular or normocellular, reflecting the ineffective hematopoiesis where cells die before reaching maturity 1, 5

When Leukocytosis Occurs in MDS

Leukocytosis in MDS is the exception, not the rule, and typically indicates specific circumstances:

  • Chronic myelomonocytic leukemia (CMML): This MDS/myeloproliferative overlap syndrome can present with elevated white blood cell counts 1
  • Progression to acute leukemia: Excessive leukocytosis may occur when MDS transforms to acute myeloid leukemia, representing "spilling of malignant blasts into the periphery" 1
  • These situations require cytoreductive therapy: When leukocytosis does occur, it may necessitate treatment with hydroxyurea or low-dose cytarabine 1

Clinical Implications

The cytopenic presentation of MDS drives the major clinical problems:

  • Infection risk from neutropenia: Requires monitoring and supportive care with growth factors in some cases 1
  • Bleeding risk from thrombocytopenia: Necessitates platelet transfusion support 1
  • Symptomatic anemia: The most frequent problem, requiring red blood cell transfusions in many patients 1

Common Pitfall to Avoid

Do not confuse a hypercellular bone marrow with peripheral leukocytosis. MDS characteristically shows hypercellular marrow with peripheral cytopenias—this dissociation is a hallmark of the disease's ineffective hematopoiesis 1, 5. The cells are produced but die prematurely in the marrow (apoptosis) rather than maturing and entering the peripheral blood 5.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Diagnostic Criteria for Myelodysplastic Syndromes (MDS)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.